Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.
about
Vitamin D and its role during pregnancy in attaining optimal health of mother and fetus.The role of vitamin D in cancer preventionVitamin D pathway gene variants and prostate cancer prognosisVitamin D and Colorectal, Breast, and Prostate Cancers: A Review of the Epidemiological EvidenceVitamin D and Immune Response: Implications for Prostate Cancer in African AmericansLifestyle and dietary factors in the prevention of lethal prostate cancerA prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancerInteractions between plasma levels of 25-hydroxyvitamin D, insulin-like growth factor (IGF)-1 and C-peptide with risk of colorectal cancerSerum 25-hydroxyvitamin D and risk of lung cancer in male smokers: a nested case-control studyThe role of vitamin D in pregnancy and lactation: emerging concepts.Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study.Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort.The impact of delayed blood centrifuging, choice of collection tube, and type of assay on 25-hydroxyvitamin D concentrationsLong-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialVitamin D levels and deficiency with different occupations: a systematic reviewPrediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer.Genome-wide association study of circulating vitamin D levels.Vitamin D deficiency predicts prostate biopsy outcomes.Circulating 25-hydroxyvitamin D and risk of endometrial cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.Circulating 25-hydroxyvitamin D and risk of non-hodgkin lymphoma: Cohort Consortium Vitamin D Pooling Project of Rarer CancersCirculating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer CancersVitamin D and pancreatic cancer.Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma.Serum levels of vitamin D, parathyroid hormone and calcium in relation to survival following breast cancer.Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and gradeEffect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin D level: Implications for meta-analyses and setting vitamin D guidelines.Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone statusLow vitamin D status and suicide: a case-control study of active duty military service members.Role of hormonal and other factors in human prostate cancer.Plasma insulin-like growth factor-1 level and risk of incident hypertension in nondiabetic womenSerum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening TrialPlasma 25-hydroxyvitamin D and its genetic determinants in relation to incident myocardial infarction and stroke in the European prospective investigation into cancer and nutrition (EPIC)-Germany studySerum vitamin D and the risk of Parkinson disease.Serum 25-hydroxyvitamin D and risks of colon and rectal cancer in Finnish men.Vitamin D receptor protein expression in tumor tissue and prostate cancer progression.Serum 25-hydroxyvitamin D and risk of oropharynx and larynx cancers in Finnish men.Vitamin D status and community-acquired pneumonia: results from the third National Health and Nutrition Examination Survey
P2860
Q22305602-E358A586-A2C2-4BD6-BB1E-A5550F92D969Q24545572-CFDED130-4BE6-4957-BAF9-FFD645FDE255Q24628345-AB37B217-3D78-483B-8A95-3E1F07B3E2D4Q26766256-59CD944C-FD6D-4756-9896-9D891567F5D3Q26768536-25009C2B-0CC3-439F-BC45-AACC2983254FQ27025735-B2C9845D-1905-4DB6-88CE-CF8426FB739CQ28221539-F346EE30-5EDE-4B6F-924B-564514D121DFQ28740805-8EC1BC1D-3DFC-4797-A0C2-E4F46E69B45CQ28743755-EFAA2ADA-62D7-4234-B786-A805E5444024Q30416484-B31E218D-1C8C-4DEE-98A4-FCA37DB531C0Q33580672-31A804D8-5A84-4307-A027-0BCEDBBCB171Q33688029-D9FC3B4D-1CF7-4689-9F2E-60783D22BDBAQ33712468-9050F44E-D90F-4D2A-A340-E9070D1DCA7EQ33768535-7A6C1F58-FBE0-4EBF-A2BB-2BF8581556E0Q33803855-02643F4F-63C8-42BA-A797-7683D6FACBCDQ33823501-3B641918-522F-4914-906F-8BC8EF2684FDQ33873649-A51C2E2C-4848-4A1C-A109-6AD1DCFCDAF7Q33904451-1AD6A610-B36B-430C-8C89-379D179FD332Q33923335-6CC97C93-4519-43C2-9606-2EAE18939957Q33942574-9364A77E-F9B1-4C78-B85D-0920E6F9CA99Q33942587-95C3B219-B167-4AD0-85CF-963060669775Q33942593-F582AE98-FB20-4BA1-A06B-C0A5085A1D06Q33942599-9B4C8019-76AB-49AA-A964-D3A5D9A5A858Q33942612-6346FAF7-6E17-4E6A-8F23-A9729DBDBF6BQ34009515-95069D7C-1664-4EE7-AE4B-A5F789692EEFQ34115732-51B5211A-F945-4491-B829-EB6C60F76B0AQ34136443-81339A3A-8293-41B8-9AB2-93E28B3122A1Q34228158-A7D7A25E-BD45-4D02-8BF5-10E3A183029AQ34235424-D7625E25-610F-4A55-BE99-BE6B935BDBEBQ34414233-87B37721-1436-4BB3-8C4C-A128E2E5C550Q34544473-5BE20CF4-2A86-4032-B28E-DD0FFDB58F5FQ34764764-70AAB5FA-0449-4528-827C-9D4AAB69D4EFQ34812753-B0B544A8-B17F-49E7-BC81-0018BCBF228AQ34898979-CA302E06-F7D4-4F66-88FA-229E5F85F5A0Q34919132-6382756D-4EB8-4A28-959B-375708CD6F98Q34962536-2A4598AE-0F75-4282-978A-6F013368068BQ35017919-8C4B1211-B7FC-428A-BE8B-6CD0162B9F6FQ35023459-7F7AF477-27D1-422B-8896-48677114B12BQ35036628-E6BD58E2-796A-4B01-96BF-8D92DE888CD9Q35049459-EF7455DA-332E-46D7-89EE-714DDFC27E9D
P2860
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.
@en
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.
@nl
type
label
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.
@en
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.
@nl
prefLabel
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.
@en
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.
@nl
P2093
P1476
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.
@en
P2093
Bruce W Hollis
Elizabeth A Platz
Walter C Willett
P304
P356
10.1023/B:CACO.0000024245.24880.8A
P577
2004-04-01T00:00:00Z
P6179
1043033731